Dos and don’ts in VC interactions
VCs invested $14 billion in biopharma startups in 2019, helping these companies survive and grow past the cash draining development phases. Are you out there looking to get a piece of the 2020 funding cake? We’re here to help! MSC Associate Stephanie Mattson, with experience from one of Sweden’s largest life science funds, shares the dos and don’ts of interacting with VCs – and it might make or break your deal.
August 26, 2020
Our success depends on how well our clients perform. We are here to equip them with the right tools and empower them with the right insight, so they confidently can strike deals, partnerships and attract investments.
We understand the business issues facing smaller biotech companies and share a passion with our clients to drive the future of medicine.
We support leaders with actionable recommendations and insights with a fervor and razor-sharp focus. Our approach is doing so by creating tailored solutions to challenging business issues and crafting strategies to achieve business goals and brand visibility. Whether it is business development, asset valuation or communication, we are a reliable partner that always walk that extra mile.